|
1
|
Sung H, Ferlay J, Siegel RL, Leversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancer in 185 countries. CA Cancer J Clin Feb 4, 2021 (Epub ahead
of print). doi: 10.3322/caac.21660.
|
|
2
|
Sylvester RJ, van der Meijden AP,
Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW and
Kurth K: Predicting recurrence and progression in individual
patients with stage Ta T1 bladder cancer using EORTC risk tables: A
combined analysis of 2596 patients from seven EORTC trials. Eur
Urol. 49:466–477. 2006.PubMed/NCBI View Article : Google Scholar
|
|
3
|
van Rhijn BW, Burger M, Lotan Y, Solsona
E, Stief CG, Sylvester RJ, Witjes JA and Zlotta AR: Recurrence and
progression of disease in non-muscle-invasive bladder cancer: From
epidemiology to treatment strategy. Eur Urol. 56:430–442.
2009.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Tilki D, Burger M, Dalbagni G, Grossman
HB, Hakenberg OW, Palou J, Reich O, Rouprêt M, Shariat SF and
Zlotta AR: Urine markers for detection and surveillance of
non-muscle invasive bladder cancer. Eur Urol. 60:484–492.
2011.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Narayan VM, Adejoro O, Schwartz I,
Ziegelmann M, Elliott S and Konety BR: The prevalence and impact of
urinary marker testing in patients with bladder cancer. J Urol.
199:74–80. 2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Bumbu GA, Berechet MC, Pop OL, Nacer K,
Bumbu G, Maghiar OA, Bratu OG, Stefanescu ML, Pantis C and Bumbu
BA: Primary malignant melanoma of the bladder-case report and
literature overview. Rom J Morphol Embryol. 60:287–292.
2019.PubMed/NCBI
|
|
7
|
Witjes JA, Morote J, Cornel EB, Gakis G,
van Valenberg FJP, Lozano F, Sternberg IA, Willemsen E, Hegemann
ML, Paitan Y and Leibovitch I: Performance of the bladder EpiCheck™
methylation test for patients under surveillance for
non-muscle-invasive bladder cancer: Results of a Multicenter,
Prospective, Blinded Clinical Trial. Eur Urol Oncol. 1:307–313.
2018.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Su SF, de Castro Abreu AL, Chihara Y, Tsai
Y, Andreu-Vieyra C, Daneshmand S, Skinner EC, Jones PA, Siegmund KD
and Liang G: A panel of three markers hyper- and hypomethylated in
urine sediments accurately predicts bladder cancer recurrence. Clin
Cancer Res. 20:1978–1989. 2014.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Goessl C, Müller M, Straub B and Miller K:
DNA alteration in body fluids as molecular tumor markers for
urological malignancies. Eur Urol. 41:668–676. 2002.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Pu RT, Laitala LE and Clark DP:
Methylation profiling of urothelial carcinoma in bladder biopsy and
urine. Acta Cytol. 50:499–506. 2006.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Hauser S, Kogej M, Fechner G, VON Pezold
J, Vorreuther R, Lummen G, Muller SC and Ellinger J: Serum DNA
hypermethylation in patients with bladder cancer: Results of a
prospective multicenter study. Anticancer Res. 33:779–784.
2013.PubMed/NCBI
|
|
12
|
Pietrusinski M, Kȩpczyński Ƚ, Jedrzejczyk
A, Borkowska E, Traczyk-Borszynska M, Constantinou M, Kauzewski B
and Borowiec M: Detection of bladder cancer in urine sediments by a
hypermethylation panel of selected tumor suppressor genes. Cancer
Biomark. 18:47–59. 2017.PubMed/NCBI View Article : Google Scholar
|
|
13
|
van der Heijden AG, Mengual L,
Ingelmo-Torres M, Lozano JJ, van Rijt-van de Westerlo CCM, Baixauli
M, Geavlete B, Moldoveanud C, Ene C, Dinney CP, et al: Urine
cell-based DNA methylation classifier for monitoring bladder
cancer. Clin Epigenetics. 10(71)2018.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Roperch JP, Grandchamp B, Desgrandchamps
F, Mongiat-Artus P, Ravery V, Ouzaid I, Roupret M, Phe V, Ciofu C,
Tubach F, et al: Promoter hypermethylation of HS3ST2, SEPTIN9 and
SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary
assay for diagnosis and surveillance in patients with low or
high-risk non-muscle-invasive bladder cancer. BMC Cancer.
16(704)2016.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Peng M, Chen C, Hulbert A, Brock MV and Yu
F: Non-blood circulating tumor DNA detection in cancer. Oncotarget.
8:69162–69173. 2017.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Bosschieter J, Lutz C, Segerink LI, Vis
AN, Zwarthoff EC, A van Moorselaar RJ, van Rhijn BW, Heymans MW,
Jansma EP, Steenbergen RD and Nieuwenhuijzen JA: The diagnostic
accuracy of methylation markers in urine for the detection of
bladder cancer: A systematic review. Epigenomics. 10:673–687.
2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Brisuda A, Pazourkova E, Soukup V, Horinek
A, Hrbacek J, Capoun O, Svobodova I, Pospisilova S, Korabecna M,
Mares J, et al: Urinary Cell-Free DNA quantification as
Non-Invasive biomarker in patients with bladder cancer. Urol Int.
96:25–31. 2016.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Qin Z, Ljubimov VA, Zhou C, Tong Y and
Liang J: Cell-free circulating tumor DNA in cancer. Chin J Cancer.
35(36)2016.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Seripa D, Parrella P, Gallucci M, Gravina
C, Papa S, Fortunato P, Alcini A, Flammia G, Lazzari M and Fazio
VM: Sensitive detection of transitional cell carcinoma of the
bladder by microsatellite analysis of cells exfoliated in urine.
Int J Cancer. 95:364–369. 2001.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Wiklund ED, Gao S, Hulf T, Sibbritt T,
Nair S, Costea DE, Villadsen SB, Bakholdt V, Bramsen JB, Sørensen
JA, et al: MicroRNA alterations and associated aberrant DNA
methylation patterns across multiple sample types in oral squamous
cell carcinoma. PLoS One. 6(e27840)2011.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Bryzgunova OE and Laktionov PP:
Extracellular nucleic acids in urine: Sources, structure,
diagnostic potential. Acta Naturae. 7:48–54. 2015.PubMed/NCBI
|
|
22
|
Dudley JC, Schroers-Martin J, Lazzareschi
DV, Shi WY, Chen SB, Esfahani MS, Trivedi D, Chabon JJ, Chaudhuri
AA, Stehr H, et al: Detection and surveillance of bladder cancer
using urine tumor DNA. Cancer Discov. 9:500–509. 2019.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Sasaki H, Yoshiike M, Nozawa S, Usuba W,
Katsuoka Y, Aida K, Kitajima K, Kudo H, Hoshikawa M, Yoshioka Y, et
al: Expression level of urinary MicroRNA-146a-5p is increased in
patients with bladder cancer and decreased in those after
transurethral resection. Clin Genitourin Cancer. 14:e493–e499.
2016.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Fan Y, Shen B, Tan M, Mu X, Qin Y, Zhang F
and Liu Y: Long non-coding RNA UCA1 increases chemoresistance of
bladder cancer cells by regulating Wnt signaling. FEBS J.
281:1750–1758. 2014.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Peter S, Borkowska E, Drayton RM, Rakhit
CP, Noon A, Chen W and Catto JW: Identification of differentially
expressed long noncoding RNAs in bladder cancer. Clin Cancer Res.
20:5311–5321. 2014.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Du L, Duan W, Jiang X, Zhao L, Li J, Wang
R, Yan S, Xie Y, Yan K, Wang Q, et al: Cell-free lncRNA expression
signatures in urine serve as novel non-invasive biomarkers for
diagnosis and recurrence prediction of bladder cancer. J Cell Mol
Med. 22:2838–2845. 2018.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Neuhausen A, Florl AR, Grimm MO and Schulz
WA: DNA methylation alterations in urothelial carcinoma. Cancer
Biol Ther. 5:993–1001. 2006.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Sethi S, Sethi S and Bluth MH: Clinical
implication of microRNAs in molecular pathology: An update for
2018. Clin Lab Med. 38:237–251. 2018.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Xiao S, Wang J and Xiao N: MicroRNAs as
noninvasive biomarkers in bladder cancer detection: A diagnostic
meta-analysis based on qRT-PCR data. Int J Biol Markers.
31:e276–e285. 2016.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Hanke M, Hoefig K, Merz H, Feller AC,
Kausch I, Jocham D, Warnecke JM and Sczakiel G: A robust
methodology to study urine microRNA as tumor marker: microRNA-126
and microRNA-182 are related to urinary bladder cancer. Urol Oncol.
28:655–661. 2010.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Chen YH, Wang SQ, Wu XL, Shen M, Chen ZG,
Chen XG, Liu YX, Zhu XL, Guo F, Duan XZ, et al: Characterization of
microRNAs expression profiling in one group of Chinese urothelial
cell carcinoma identified by Solexa sequencing. Urol Oncol.
31:219–227. 2013.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Braicu C, Cojocneanu-Petric R, Chira S,
Truta A, Floares A, Petrut B, Achimas-Cadariu P and Berindan-Neagoe
I: Clinical and pathological implication of miRNA in bladder
cancer. Int J Nanomedicine. 10:791–800. 2015.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Eissa S, Matboli M, Essawy NO and Kotb YM:
Integrative functional genetic-epigenetic approach for selecting
genes as urine biomarkers for bladder cancer diagnosis. Tumour
Biol. 36:9545–9552. 2015.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Bianca A, Sanchez-Gonzalez A, Requena MJ,
Carrasco-Valiente J, Gomez-Gomez E, Cheng L, Cimadamore A,
Montironi R and Lopez-Beltran A: Expression of miR-100 and miR-138
as prognostic biomarkers in non-muscle-invasive bladder cancer.
APMIS. 127:545–553. 2019.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Pardini B, Cordero F, Naccarati A, Viberti
C, Birolo G, Oderda M, Di Gaetano C, Arigoni M, Martina F, Calogero
RA, et al: MicroRNA profiles in urine by next-generation sequencing
can stratify bladder cancer subtypes. Oncotarget. 9:20658–20669.
2018.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Hofbauer SL, de Martino M, Lucca I, Haitel
A, Susani M, Shariat SF and Klatte T: A urinary microRNA (miR)
signature for diagnosis of bladder cancer. Urol Oncol.
36:531.e1–531.e8. 2018.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Kim WT, Kim YH, Jeong P, Seo SP, Kang HW,
Kim YJ, Yun SJ, Lee SC, Moon SK, Choi YH, et al: Urinary cell-free
nucleic acid IQGAP3: A new non-invasive diagnostic marker for
bladder cancer. Oncotarget. 9:14354–14365. 2018.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Zhang M, Ren B, Li Z, Niu W and Wang Y:
Expression of N-Myc downstream-regulated gene 2 in bladder cancer
and its potential utility as a urinary diagnostic biomarker. Med
Sci Monit. 23:4644–4649. 2017.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Armstrong DA, Green BB, Seigne JD, Schned
AR and Marsit CJ: MicroRNA molecular profiling from matched tumor
and bio-fluids in bladder cancer. Mol Cancer.
14(194)2015.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Andreu Z, Otta Oshiro R, Redruello A,
Lopez-Martin S, Gutiérrez-Vázquez C, Morato E, Marina AI, Olivier
Gómez C and Yáñez-Mó M: Extracellular vesicles as a source for
non-invasive biomarkers in bladder cancer progression. Eur J Pharm
Sci. 98:70–79. 2017.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Berrondo C, Flax J, Kucherov V, Siebert A,
Osinski T, Rosenberg A, Fucile C, Richheimer S and Beckham CJ:
Expression of the Long Non-Coding RNA HOTAIR correlates with
disease progression in bladder cancer and is contained in bladder
cancer patient urinary exosomes. PLoS One.
11(e0147236)2016.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Chen CL, Lai YF, Tang P, Chien KY, Yu JS,
Tsai CH, Chen HW, Wu CC, Chung T, Hsu CW, et al: Comparative and
targeted proteomic analyses of urinary microparticles from bladder
cancer and hernia patients. J Proteome Res. 11:5611–5629.
2012.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Beckham CJ, Olsen J, Yin PN, Wu CH, Ting
HJ, Hagen FK, Scosyrev E, Messing EM and Lee YF: Bladder cancer
exosomes contain EDIL-3/Del1 and facilitate cancer progression. J
Urol. 192:583–592. 2014.PubMed/NCBI View Article : Google Scholar
|
|
44
|
de Martino M, Shariat SF, Hofbauer SL,
Lucca I, Taus C, Wiener HG, Haitel A, Susani M and Klatte T: Aurora
A kinase as a diagnostic urinary marker for urothelial bladder
cancer. World J Urol. 33:105–110. 2015.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Pozzi V, Di Ruscio G, Sartini D, Campagna
R, Seta R, Fulvi P, Vici A, Milanese G, Brandoni G, Galosi AB, et
al: Clinical performance and utility of NNMT-based urine test for
bladder cancer. Int J Biol Markers. 33:94–101. 2018.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Choi S, Shin JH, Lee YR, Joo HK, Song KH,
Na YG, Chang SJ, Lim JS and Jeon BH: Urinary APE1/Ref-1: A
potential bladder cancer biomarker. Dis Markers.
2016(7276502)2016.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Rosso O, Piazza T, Bongarzone I, Rosello
A, Mezzanzanica D, Canevari S, Orengo AM, Puppo A, Ferrini S and
Fabbi M: The ALCAM shedding by metalloprotease ADAM17/TACE is
involved in motility of ovarian carcinoma cells. Mol Cancer Res.
5:1246–1253. 2007.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Ecke TH, Weiß S, Stephan C, Hallmann S,
Barski D, Otto T and Gerullis H: UBC® Rapid Test for
detection of carcinoma in situ for bladder cancer. Tumour Biol.
39(1010428317701624)2017.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Schiffer E, Vlahou A, Petrolekas A,
Stravodimos K, Tauber R, Geschwend JE, Neuhaus J, Stolzenburg JU,
Conaway MR, Mischak H and Theodorescu D: Prediction of
muscle-invasive bladder cancer using urinary proteomics. Clin
Cancer Res. 15:4935–4943. 2009.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Chen YT, Chen CL, Chen HW, Chung T, Wu CC,
Chen CD, Hsu CW, Chen MC, Tsui KH, Chang PL, et al: Discovery of
novel bladder cancer biomarkers by comparative urine proteomics
using iTRAQ technology. J Proteome Res. 9:5803–5815.
2010.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Soukup V, Kalousova M, Capoun O, Sobotka
R, Breyl Z, Pesl M, Zima T and Hanus T: Panel of urinary diagnostic
markers for non-invasive detection of primary and recurrent
urothelial urinary bladder carcinoma. Urol Int. 95:56–64.
2015.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Blanca A, Requena MJ, Alvarez J, Cheng L,
Montironi R, Raspollini MR, Reymundo C and Lopez-Beltran A: FGFR3
and Cyclin D3 as urine biomarkers of bladder cancer recurrence.
Biomark Med. 10:243–253. 2016.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Shen C, Sun Z, Chen D, Su X, Jian J, Li G,
Lin B and Yan J: Developing urinary metabolomic signatures as early
bladder cancer diagnostic markers. OMICS. 19:1–11. 2015.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Loras A, Trassierra M, Sanjuan-Herraez D,
Martinez-Bisbal MC, Castell JV, Quintas G and Ruiz-Cerda JL:
Bladder cancer recurrence surveillance by urine metabolomics
analysis. Sci Rep. 8(9172)2018.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Wong YNS, Joshi K, Khetrapal P, Ismail M,
Reading JL, Sunderland MW, Georgiou A, Furness AJS, Ben Aissa A,
Ghorani E, et al: Urine-derived lymphocytes as a non-invasive
measure of the bladder tumor immune microenvironment. J Exp Med.
215:2748–2759. 2018.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Christensen E, Birkenkamp-Demtroder K,
Nordentoft I, Hoyer S, van der Keur K, van Kessel K, Zwarthoff E,
Agerbaek M, Orntoft TF, Jensen JB and Dyrskjøt L: Liquid biopsy
analysis of FGFR3 and PIK3CA hotspot mutations for disease
surveillance in bladder cancer. Eur Urol. 71:961–969.
2017.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Gormally E, Caboux E, Vineis P and Hainaut
P: Circulating free DNA in plasma or serum as biomarker of
carcinogenesis: Practical aspects and biological significance.
Mutat Res. 635:105–117. 2007.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Lee J, McKinney KQ, Pavlopoulos AJ, Niu M,
Kang JW, Oh JW, Kim KP and Hwang S: Altered proteome of
extracellular vesicles derived from bladder cancer patients urine.
Mol Cells. 41:179–187. 2018.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Allory Y, Beukers W, Sagrera A, Flandez M,
Marques M, Marquez M, van der Keur KA, Dyrskjot L, Lurkin I,
Vermeij M, et al: Telomerase reverse transcriptase promoter
mutations in bladder cancer: High frequency across stages,
detection in urine, and lack of association with outcome. Eur Urol.
65:360–366. 2014.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Springer SU, Chen CH, Rodriguez Pena MDC,
Li L, Douville C, Wang Y, Cohen JD, Taheri D, Silliman N, Schaefer
J, et al: Non invasive detection of urothelial cancer through the
analysis of driver gene mutation and aneuploidy. Elife.
7(e32143)2018.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Avogbe PH, Manel A, Vian E, Durand G,
Forey N, Voegele C, Zvereva M, Hosen MI, Meziani S, De Tilly B, et
al: Urinary TERT promoter mutation as non-invasive biomarkers for
the comprehensive detection of urothelial cancer. EBioMedicine.
44:431–438. 2019.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Lozano F, Raventos CX, Carrion A, Trilla E
and Morote J: Current status of genetic urinary biomarkers for
surveillance of non-muscle invasive bladder cancer: A systematic
review. BMC Urol. 20(99)2020.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Boda D: Cellomics as integrative omics for
cancer. Curr Proteomics. 10:237–245. 2013.
|
|
64
|
Neagu M, Constantin C, Tanase C and Boda
D: Patented biomarker panels in early detection of cancer. Recent
Pat Biomark. 1:10–14. 2011.
|
